Palo Alto Investors Llc acquired 92,562 shares as Vanda Pharmaceuticals Inc (VNDA)’s stock declined 5.00%. The …
Stock market analysts watching Vanda Pharmaceuticals Inc. (VNDA) have recently changed their ratings on the stock. The latest reports which are outstanding on Tuesday 8th of August state 2 analysts have a rating of “strong buy”, 4 …
Currently, Vascular Biogenics carries a Zacks Rank #3 (Hold). A better-ranked stock in the same industry is Vanda Pharmaceuticals Inc. (VNDA - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of …
Robert W. Baird has "Underperform" rating and $24 target. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has risen 51.60% since August 10, 2016 and is uptrending. The stock has "Buy" rating by Needham on Wednesday, December …
The stock decreased 3.43% or $0.55 during the last trading session ... Point72 …
The stock's average target of $55 is -8.97% below today's ($60.42) share price. Piper Jaffray maintained the shares of VNDA in report on Thursday, August 3 with "Buy" rating. Shares of Las Vegas Sands Corp. The firm has "Market …
The stock of Multi-Color Corporation (NASDAQ ... Vanda Pharmaceuticals Inc (NASDAQ:VNDA) was reduced too. Since February 8, 2017, it had 1 insider buy, and 3 sales for $8.14 million activity. Resapwn Entertainment: Titanfall 2 "Was …
The stock rose 0.03% or $0.01 reaching $30.74 per share ... Vanda Pharmaceuticals Inc (NASDAQ:VNDA) was reduced too. Among 6 analysts covering New York Mortgage Trust (NASDAQ:NYMT), 1 have Buy rating, 0 Sell and 5 Hold. …
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Stock analysts at Jefferies Group issued their Q3 2017 earnings per share (EPS) estimates for shares of Vanda Pharmaceuticals in a research note issued on Thursday. Jefferies Group …